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Abstract
Background: Complementary and alternative medicine (CAM), and herbal therapies, are accepted worldwide, and
have been important from medical, sociological and economic perspectives, among haemodialysis (HD) patients.
The primary aim of this study was to evaluate the use of CAM among patients with end-stage renal disease (ESRD)
who are undergoing HD.
Methods: Face-to-face interviews of patients with ESRD undergoing HD from ten outpatient renal departments at a
national level in Palestine were conducted from June 2014 to January 2015. A survey questionnaire, which included
questions on socio-demographic and clinical characteristics, and on the CAM therapies that were used, was
administered.
Results: Out of 267 patients interviewed, 172 patients used at least one type of CAM in the last month prior to the
interview, and thus the utilisation rate was 64.4 %. Forty one (15.4 %) patients reported using one type of CAMs, while 18.
7 % used two different CAMs and 30.3 % used more than two types of CAMs for their health status. Of the patients who
used CAM, herbal therapies were used most often (43.5 %), followed by honey (35.6 %), diet (22.8 %), and exorcism in
Islam (16.9 %). The herbal therapies mentioned most often were Nigella sativa L. (18.7 %), followed by Salvia officinalis L.
(16.9 %), and Pimpinella anisum L. (10.5 %).
Conclusions: In conclusion, the prevalence of CAM is relatively high in the selected population. Most patients used
biological therapies such as herbal remedies, thus highlighting a greater need for patient education regarding CAM
therapies and possible herb-drug interactions. Health care providers must be aware of the potential benefits and risks
related to CAM use. There is a need for more clinical research pertaining to CAM to reach stronger evidence regarding
potential benefits and risks related to CAM use.
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Background
Haemodialysis (HD) is the first-line treatment for patients
with end-stage renal disease (ESRD), designed to replace
kidney function, and it is the most extensively used tech-
nique worldwide [1–3]. Complementary and alternative
medicine (CAM), or herbal therapies, are extremely
popular worldwide and have been important among
HD patients from medical, sociological and economic
perspectives [4–6]. CAM may provide new therapeutic
opportunities for HD patients with the target of enhan-
cing quality of life and improving symptoms [7–9].
The most widely used CAM therapies include biologically
based therapies (e.g. herbal) and mind-body medicine (e.g.
yoga, spiritual healing/prayer, meditation, and hypnosis).
Despite the ubiquitous use of CAM at a global level in a
broad range of illnesses or populations, there is limited data
concerning the use of CAM or herbal therapies in patients
with ESRD [7, 8, 10–12]. To our knowledge, there were
several studies conducted on CAM, considering aspects
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other than ESRD type, such as CAM among Palestinian
hypertensive patients [13], diabetes mellitus patients [14],
cancer patients [15], or the general public [16]. There were
also several studies conducted on herbal therapies that
considered aspects other than ESRD type, such as herbal
therapies among cancer patients [17], university students
[18], geriatric patients [19], or in pregnancy [20, 21]. An
extensive search did not reveal information concerning the
use of CAM or herbal among HD patients in the Arab
Middle East where medicinal herbs, or some types of CAM
such as honey, prayers, reading holy books, Al-Hijama, fast-
ing, or exorcism in Islam are an integral part of the culture
and religion [22–27]. This study was performed to deter-
mine the prevalence and types of CAM and herbal therap-
ies used among Palestinian patients with HD. The present
study aims to contribute to this growing area of research by
helping in plan the interventions needed to improve the
self-use of CAM or herbal therapies, and by identifying the
most commonly used CAM or herbal therapies which may
form a data-base for further research. Understanding pat-
terns of CAM therapies used in HD patients will not only
help healthcare providers to provide more informed clinical
care but also assist policymakers in creating the appropriate
frameworks for future policy and direct and encourage
researchers to conduct clinical research pertaining to CAM
to reach stronger evidence regarding potential benefits and
risks related to CAM use.
Methods
Study design and setting
Data in this study was obtained from a cross-sectional
study carried out during the period: June 2014 to January
2015. Participants were recruit from ten different settings
(Abu Al hasan Al Kassem Hospital, Al Hussein Hospital,
Alia Hospital, An-najah National University teaching Hos-
pital, Darwish Nazal Hospital, Jericho Government Hos-
pital, Khalil Suliman Hospital, Ramallah’s Sons Wing
Hospital, Thabit Thabit Hospital, and Yasser Arafat Hos-
pital) representing government and non-government sec-
tors in West-Bank, Palestine to include a broad spectrum
of participant characteristics [28].
Study population
Consecutive dialysis patients from 10 outpatient renal
departments with associated dialysis units were included.
Information regarding number and geographical distri-
bution of dialysis units in West-Bank as well as the total
number of HD patients (740) at the time of study were
obtained from the Palestinian Ministry of Health and
Palestinian Central Bureau of Statistics [29].
Sample size and sampling techniques
Raosoft sample size calculator, a web-based calculator,
was used to estimate the required sample size assuming
that 50 % of the HD patients used CAM for their health
status, margin of error set at 0.05, and assuming a confi-
dence level of 95 % [30]. The required sample size was
calculated to be 254 HD patients, which was increased
to 277 for more accuracy, to account for unusable ques-
tionnaires and potential non-responses, and to increase
the generalizability of the obtained results. Participants
who met the following criteria were included in the
study: (1) patients younger than 18; (2) confirmed diag-
nosis of ESRD; and (3) on regular HD therapy for at
least 6 months. Those patients who were seriously ill or
had major psychiatric disorders at the time of study were
excluded.
Research instrument
A quantitative survey instrument was formed based on
questionnaires from previous studies [7, 8, 10–12]. The
questionnaires were prepared and evaluated for content
validity by a group of experts in the fields of nephrology,
alternative medicine, clinical pharmacy and biostatisti-
cians. The clarity and readability of the questionnaire
was pre-tested in a pilot study of 16 patients. The results
of the pilot sample were not included in the final ana-
lysis. Feedback from the participants was used to modify
and adjust the questionnaire to reach the final version of
the study tool. An additional file was provided to show
detailed description of the study both in English and
Arabic (Additional file 1).
The questionnaire consisted of four parts. The first part
was about the socio-demographic characteristics of the par-
ticipants, and recorded details of age, gender, marital status,
residency, educational level, body mass index (BMI), family
monthly income, smoking status, and occupational status.
The second part was about the clinical characteristics of
the participants, and recorded the duration of disease in
months, duration of dialysis sessions in hours, number of
dialysis per week, number of chronic diseases, and number
of medications for chronic use. The third part of the ques-
tionnaire focused on the regular consumption of CAM and
participants were asked to identify what they had used in
the last month before the survey. CAM therapies were
categorized in a list as follows: (1) Alternative Medical
Systems such as acupuncture; (2) Biologically Based Ther-
apies such as folk medicine, vitamins, or other types of
herbal products; (3) Manipulative and Body-Based Methods
such as massage or physical therapies (e.g. heat and cold, or
rehabilitation strategies); and (4) Mind-Body Medicine such
as meditation, hypnosis, walking, or music therapy [31–38].
Exorcism in Islam (ruqya) was combined with Mind-Body
Medicine, to mimic previous studies [33, 39, 40]. The last
part of the questionnaire was designed to determine the
types of herbal therapies that HD patients have used in self-
therapy practices. HD patients were requested to provide
the native name of the herb that they used as self-therapy.
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This study included all herbal remedies or other CAM
which was used only for improving or curing health condi-
tions during the dialysis care period as CAM.
Statistical analysis
All statistical analyses were conducted using the Statistical
Software Package for the Social Sciences, version 15 for
Windows (SPSS, Chicago, IL). For descriptive statistics,
means, standard deviations (SD), and medians interquartile
range [IQR]), frequencies, and percentages were computed.
Pearson Chi-Square test or Fisher’s exact test was used for
comparative analysis. A value of P < 0.05 was considered
significant.
Results
A total of 267 patients (139 males, 128 females; mean age
53.3 ± 16.2 years) receiving HD were recruited for the
study. The socio-demographic data of the study partici-
pants is listed in Table 1. The majority of patients (73.4 %)
had hypertension. Approximately two thirds (67 %) had
multiple chronic diseases, and 172 (64.4 %) were on six or
more chronic medications. Around two thirds of patients
(76.4 %) were dialyzed three times weekly, 188 patients
(70.4 %) stayed on dialysis more than three hours, and the
median duration of HD was 2 (interquartile range: 1–5
years). Demographic and clinical characteristics of the par-
ticipants are shown in Table 1.
One hundred-seventy two of the patients (64.4 %)
reported the use of one or more type of CAM therapy.
A total of 19 different CAMs were reported by HD
patients (Table 2). A total of 486 CAM episodes were
reported by all HD patients, giving an average utilisation
rate of 1.8 ± 1.9. The CAM users among the dialysis
patients had used a median of one CAM, and a max-
imum of nine types. Forty one (15.4 %) patients reported
using one type of CAM, while 18.7 % used two different
CAMs and 30.3 % used more than two types of CAM
for their health. Of the patients who used CAM, herbal
therapy was used most often (43.5 %), followed by honey
(35.6 %), diet (22.8 %), and exorcism in Islam (16.9 %);
(Table 2). CAM use was distributed throughout the popu-
lation in regards to the socio-demographic and clinical
characteristics in Table 1. A comparison of the character-
istics of users and nonusers of CAM showed that there
was no significant difference (p-value > 0.05) in all socio-
demographics and clinical characteristics except in their
income, and the number of dialysis sessions per week
which showed a significant difference (p-value < 0.05).
A total of 20 different herbal therapies were reported
by HD patients (Table 3). Herbal therapies mentioned
most often were Nigella sativa L. (18.7 %), followed by
Salvia officinalis L. (16.9 %), and Pimpinella anisum L.
(10.5 %); (Table 3). Fifty two (19.5 %) patients reported
using one type of herbal therapy, 10.1 % reported using
two types of herbal therapy, and 13.9 % reported using
more than two types of herbal therapies for their health.
Discussion
This cross-sectional study documents the utilisation pat-
tern of CAMs among HD in 10 haemodialysis centres in
West Bank, Palestine. The participants are considered
representative of patients with ESRD in Palestine since
the haemodialysis centres are located in all districts of
Palestine. The use of CAM has been reported among
HD patients at a global level [7, 8, 10–12], however, the
current study is the first to assess the use of CAM
among a sample of HD patients in Palestine.
Many of the patients that we studied reported the use
of certain types of CAM therapies in their health self-
management. These therapies were mainly home herbal
remedies. Around two thirds of HD patients in our study
reported the use of one, or more than one, type of CAM
therapy, which is in agreement with other published
studies among HD or other chronic diseases [8, 10, 41,
42]. Use of CAM or herbal remedies among Palestinian
people and Arab or Muslim populations in general is
driven by culture, history, sometimes religion, and some-
times by herbalists spread all over the country rather by
advice from healthcare providers [22–27, 43, 44]. Based
on this, the investigators did address the question “who
recommends these herbs to HD patients” because of the
many possible confounding factors. Furthermore, none
of the herbal remedies used by HD patients are present
in the essential drug list of the Palestinian ministry of
health and are not covered by health insurance which
made their use to be outside the context of prescribed
medicines [45, 46].
It is noteworthy that the consumption of herbal remed-
ies reported in our study was more prevalent in dialysis
patients than that in other published data [10, 11]. Herbal
remedies were of interest in this study because they are
usually considered intrinsically safe and beneficial, and are
frequently consumed in large quantities by ESRD patients
[10, 11, 47–49]. Nigella sativa L., and Salvia officinalis L.
were among the most common herb reported in the
current study as well, which is interesting because exten-
sive research studies on Nigella sativa L., and Salvia offici-
nalis L. have indicated a renoprotective effects of these
herbs [50–52].
However, because herbal constituents and bioactive
phytochemical compounds might interact with patient’s
medications, their use is not always safe for HD patients
[53–57]. The use of herbal medicines in HD patients
seems to bear more risk compared tothe general population
[11]. It is mainly due to accumulation of toxic material of
herbal remedies in patients with kidney malfunction. Tox-
icity of herbal therapies may be caused by the different ac-
tive constituents; or contaminants, or potential interactions
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Table 1 Socio-demographic and clinical characteristics of the study population (n = 267) and their association with CAM use
Variable Overall N (%) N =267 CAM users N (%) N = 172 Non-CAM users N (%) N = 95 P value
Age category (year) 0.093
< 40 58 (21.7) 42 (24.4) 16 (16.8)
40–59 97 (36.3) 66 (38.4) 31 (32.6)
≥ 60 112 (41.9) 64 (37.2) 48 (50.5)
Gender 0.899
Male 139 (52.1) 89 (51.7) 50 (52.6)
Female 128 (47.9) 83 (48.3) 45 (47.4)
BMI 0.323
Underweight 24 (9) 16 (9.4) 8 (9.3)
Normal 97 (36.3) 71 (41.8) 26 (30.2)
Overweight 27 (28.1) 44 (25.9) 28 (32.6)
Obese 63 (23.6) 39 (22.9) 24 (27.9)
Education 0.112
Not educated 40 (15.0) 21(12.2) 19 (15)
Elementary school (primary) 71 (26.6) 42 (24.4) 29 (30.5)
High school (secondary school) 102 (38.2) 69 (40.1) 33 (34.7)
University 54 (20.2) 40 (23.3) 14 (14.7)
Income 0.006
Moderate to high (≥2000 NIS) 100 (37.5) 75 (43.6) 25 (26.3)
Low (<2000 NIS) 167 (62.5) 97(56.4) 70 (73.7)
Living 0.559
City 84 (31.5) 58 (33.7) 26 (27.4)
Village 161 (60.3) 100 (58.1) 61 (64.2)
Palestinian refugee camps 22 (8.2) 14 (8.1) 8 (8.4)
Marital Status 0.404
Married 188 (70.4) 118 (68.6) 70 (73.7)
Not married 79 (29.6) 54 (20.2) 25 (26.3)
Occupation 0.706
Unemployed 232 (86.9) 148 (86.0) 84 (88.4)
Employed 35 (13.1) 24 (14.0) 11 (11.6)
Duration of dialysis (month) 0.343
< 12 58 (21.7) 40 (23.3) 18 (18.9)
12–49 119(44.6) 71 (41.3) 48 (50.5)
≥ 50 90 (33.7) 61 (35.5) 29 (30.5)
Number of dialysis sessions per week <0.001
≤ 2 26 (9.7) 14 (8.1) 12 (12.6)
3 204 (76.4) 144 (83.7) 60 (63.2)
≥ 4 37 (13.9) 14 (8.1) 23 (24.2)
Dialysis in a day (hours) 0.066
≤ 3 79 (29.6) 43(25.0) 36 (37.9)
> 3- < 4 119 (44.6) 84 (48.8) 35 (36.8)
≥ 4 69 (25.8) 45 (26.2) 24 (25.3)
Transplantation history 0.830
Yes 26 (9.7) 16 (9.3) 10 (10.5)
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with other herbs and drugs [58]. More recent studies dem-
onstrated that herbal medicines were associated with en-
hanced ESRD risk in patients with CKD [59, 60]. Senna,
chamomile, and fenugreek were among the most common
herbs reported in the current study as well, which is
Table 1 Socio-demographic and clinical characteristics of the study population (n = 267) and their association with CAM use
(Continued)
No 241 (90.3) 156 (90.7) 85 (89.5)
Total chronic co-morbid disease 0.959
Non 26 (9.7) 18 (10.5) 8 (8.4)
1 62 (23.2) 40 (23.3) 22 (23.2)
2 63 (23.6) 40 (23.3) 23 (24.2)
≥ 3 116 (43.4) 74 (43.0) 42 (44.2)
Presence of diabetes mellitus 0.091
Yes 122 (45.7) 72 (59.0) 50 (52.6)
No 145 (54.3) 100 (58.1) 45 (47.4)
Presence of hypertension 0.940
Yes 196 (73.4) 126 (73.3) 70 (73.7)
No 71 (26.6) 46 (26.7) 25 (26.3)
Chronic medication (per day) 0.393
< 6 95 (35.6) 58 (33.7) 37 (38.9)
≥ 6 172 (64.4) 114 (66.3) 58 (61.1)
Abbreviations: BMI body mass index, CAM Complementary and alternative medicine, NIS New Israeli Shekel
Table 2 Type of complementary and alternative medicine
therapies used by the patients
CAM type Frequency (%)a
Biologically Based Therapies 161 (60.3)
Herbal therapy 116 (43.5)
Honey 95 (35.6)
Diet therapy 61 (22.8)
Folk medicine 39 (14.6)
Manipulative and Body-Based Methods 39 (14.6)
Massage 26 (9.7)
Physiotherapist 23 (8.6)
Mind-Body Medicine 76 (25.1)
Exorcism in Islam (ruqya) 45 (16.9)









Applaud Islamist 1 (0.4)
Silence 1 (0.4)
Alternative Medical Systems 5 (1.9)
Acupuncture 5 (1.9)
Abbreviation: CAM Complementary and alternative medicine
aColumn total exceeds 100 % as data are overlapping because participants
used more than one type of CAM therapy
Table 3 Distribution of herbal supplements
Herbs Frequency (%)
Black cumin seed (Nigella sativa L.) 50 (18.7)
Sage (Salvia officinalis L.) 45 (16.9)
Anise (Pimpinella anisum L.) 28 (10.5)
Chamomile (Matricaria chamomilla L.) 28 (10.5)
Senna (Senna alexandrina Mill.) 23 (8.6)
Gum Arabic (Acacia senegal (L.) Willd) 22 (8.2)
Spearmint (Mentha spicata L.) 13 (4.9)
Parsley (Petroselinum crispum (Mill.) Fuss) 12 (4.5)
Fenugreek (Trigonella foenum-graecum L.) 12 (4.5)
Barley water (Hordeum vulgare L.) 9 (3.4)
Ginger (Zingiber officinale Roscoe) 2 (0.7)
Green Tea (Camellia sinensis (L.) Kuntze) 2 (0.7)
Large-leaved lime (Tilia platyphyllos Scop.) 2 (0.7)
Ivy (Hedera helix L.) 1 (0.4)
Ginseng (Panax ginseng C.A. Mey) 1 (0.4)
Hawthorn (Crataegus pinnatifida Bunge) 1 (0.4)
Caraway (Carum carvi L.) 1 (0.4)
Olive leaves (Olea europaea L.) 1 (0.4)
Cinnamon (Cinnamomum verum J. Presl) 1 (0.4)
Verbena (Verbena officinalis L.) 1 (0.4)
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interesting that senna can lead to electrolyte imbalance
especially hypokalemia [61]. Chamomile and fenugreek also
causes nephrotoxicities [62, 63].
Patients with renal problem are at risk of herb-drug inter-
actions through different mechanisms (e.g. triggered activity
changes of cytochrome P-450 isoenzyme metabolism and
drug transport proteins for many drugs such as antihyper-
tensives, anticoagulants, antidiabetics) [55]. Herb-drug in-
teractions may often be unobserved because healthcare
providers are not well-informed about potential herbal-
drug interactions occurring in HD patients [54, 55, 64, 65].
Renal impairment exposes patients to the risks of herbal
remedies such as electrolyte imbalances [11, 66]. Con-
versely, herbal remedies used by HD patients may have
numerous possible benefits such as decreasing cutaneous
pruritus, oxidative stress status, muscle cramps, and dialysis
frequency [67, 68] or reducing proteinuria and increasing
serum albumin and haemoglobin [69].
Mind-body practices such as yoga, meditation, or pro-
gressive relaxation, were the least common CAM type
recognised by the participants. However, exorcism was the
most common CAM type recognized by the participants.
A survey of patients with ESRD in the USA reported that
42 % used mind-body practices [8]. Several studies have
demonstrated that mind-body practices may be beneficial
for patients with ESRD [70, 71]. Mind–body medicine,
such as relaxation, or exorcism often involves inexpensive
self-care–based actions and appears to have minimal side
effects, risks, or interactions with conventional treatment
[7]. Exorcism in Islam (ruqya) is frequently used for heal-
ing in the Muslim world [33, 39, 40].
The most important implication of the current study is
that in the past decade there has been a remarkable in-
crease in the use of CAM therapies in HD patients. Health-
care providers thus need to be fully aware of the commonly
used CAM therapies in their culture, and provide the
correct information about the benefits or risks related to
CAM therapies that may be used by HD patients [57, 65].
It is essential for healthcare providers to be familiar with
the evidence-based medicine related to herbal remedies for
HD patients. Evidence is also required to evaluate CAM
therapies that may be not harmful most of the time (e.g.
prayer, or relaxation), compared with those that may poten-
tially be harmful (e.g. herbal therapy). The current study
provides information about the different types of CAM
used by HD patients. This information should be helpful to
healthcare providers in identifying patients who should be
given focused education about the potential benefits and
risks of unproved therapies for HD patients [57, 64, 65].
The key strengths of this study are that it includes a
multi-district sample; is a national survey with a high re-
sponse rate, and a large sample size. This study has some
limitations worth mentioning: it is limited by its cross-
sectional design, and the results are subject to recall bias
regarding CAM use. The convenience sampling method
(non-random) is considered as source of bias since it will
produce a non representative sample. Another limitation
is that this study only assessed HD patients’ practises
towards CAM and did not survey physicians’ attitude or
other health care providers who also provide medical care
to HD patients.
Conclusions
In conclusion, the prevalence of CAM is relatively high in
the selected population. Most patients used biologically-
based therapies such as herbal remedies, thus highlighting a
greater need for patient education regarding CAM therap-
ies and their possible herb-drug interactions. Health care
providers must be aware of the potential benefits and risks
related to CAM use. There is a need for more clinical
research pertaining to CAM to reach stronger evidence
regarding potential benefits and risks related to CAM use.
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